You are here: HomeNewsHealth2021 03 21Article 424561

Health News of Sunday, 21 March 2021

Source: www.today.ng

NAFDAC advises Nigerians to ensure vaccines have original AstraZeneca labels

A dose of the Astrazeneca vaccine A dose of the Astrazeneca vaccine

The National Agency for Food and Drug Administration and Control (NAFDAC), has advised Nigerians to ensure the Astrazeneca vaccine being administered on them had the original label.

The agency said the warning was imperative to ensure people did not risk being vaccinated with a fake Astrazeneca vaccine.

The position of NAFDAC is contained in a statement signed by the agency’s Director General, Mojisola Adeyeye, on Sunday, in Abuja.

Mrs Adeyeye explained that the original Astrazeneca Oxford University (AZOU) vaccine, had been contracted to India’s world largest vaccine manufacturer, Serum Institute of India (SIIPL), to produce in large quantity.

“AZOU gave the license of its vaccine to Serum Institute of India PVT Ltd, (SIIPL), to manufacture this vaccine at a commercial scale. SIIPL is the largest vaccine manufacturer in the world and the company got the license by signing the manufacturing agreement.

“SIIPL gave the vaccine the trade name COVISHIELD, it is the result of a cooperation and a technology transfer from AstraZeneca – University of Oxford to SIIPL.

“SIIPL is now the world’s largest vaccine manufacturer by number of doses produced and sold globally.

“More than 1.5 billion doses, which include Polio vaccine, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella,” she said.

Adeyeye added that the vaccines manufactured by SIIPL were accredited by the World Health Organisation (WHO), and were being used in about 170 countries across the globe in their national immunisation programme.

She added that both COVISHIELD manufactured by SIIPL and COVID-19 vaccine Astrazeneca, manufactured by Astrazeneca/Oxford University vaccine are the same vaccine.

According to Adeyeye, the vaccine was granted Emergency Use Listing (EUL) by the World Health Organisation on February 15, and it is one of the listed vaccines under the COVAX Facility.